Skip to content

OS THERAPIES INCORPORATED: 10-Q filed 2025-08-18

What OS THERAPIES INCORPORATED reported in its quarterly report filed 2025-08-18 (fiscal Q2 2025): 28 published measures, 80 facts as tagged in accession 0001213900-25-077916.

This filing

Form
10-Q (quarterly report)
Filed
2025-08-18
Fiscal period
fiscal Q2 2025
Accession
0001213900-25-077916 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All OS THERAPIES INCORPORATED filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-06-3010,310,475USD
At 2024-12-315,538,797USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-06-303,558,034USD
At 2024-12-314,727,310USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-06-304,943,647USD
At 2025-03-31-4,186,578USD
At 2024-12-31-3,266,538USD
At 2024-06-30-27,063,937USD
At 2024-03-31-25,506,457USD
At 2023-12-31-24,016,215USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-4,536,622USD91
2025-01-01 to 2025-06-30-8,413,481USD181
2025-01-01 to 2025-03-31-3,876,859USD90
2024-04-01 to 2024-06-30-1,557,480USD91
2024-01-01 to 2024-06-30-3,016,472USD182
2024-01-01 to 2024-03-31-1,458,992USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-5,802,138USD181
2024-01-01 to 2024-06-30-1,522,920USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-06-303,537,047USD181
2024-01-01 to 2024-06-301,578,863USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-466,423USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-06-30-46,845,856USD
At 2024-12-31-38,432,375USD

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-04-01 to 2025-06-3025,114,460shares91
2025-01-01 to 2025-06-3025,062,494shares181
2024-04-01 to 2024-06-305,991,041shares91
2024-01-01 to 2024-06-305,847,955shares182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-0.19USD/shares91
2025-01-01 to 2025-06-30-0.35USD/shares181
2024-04-01 to 2024-06-30-0.26USD/shares91
2024-01-01 to 2024-06-30-0.52USD/shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-0.19USD/shares91
2025-01-01 to 2025-06-30-0.35USD/shares181
2024-04-01 to 2024-06-30-0.26USD/shares91
2024-01-01 to 2024-06-30-0.52USD/shares182

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-06-303,880USD
At 2024-12-315,270USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-04-01 to 2025-06-30905,182USD91
2025-01-01 to 2025-06-301,846,465USD181
2025-01-01 to 2025-03-31941,283USD90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-4,838,728USD91
2025-01-01 to 2025-06-30-9,838,214USD181
2024-04-01 to 2024-06-30-779,800USD91
2024-01-01 to 2024-06-30-1,410,032USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-06-303,553,976USD
At 2024-12-315,533,527USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-06-303,458,034USD
At 2024-12-314,627,310USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-06-302,702,724USD
At 2024-12-311,662,068USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2025-06-306,864,438USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-04-01 to 2025-06-302,499,498USD91
2025-01-01 to 2025-06-303,808,653USD181
2024-04-01 to 2024-06-30396,567USD91
2024-01-01 to 2024-06-30758,376USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-06-3029,664,916shares
At 2024-12-3120,869,908shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-06-302,802,013USD
At 2024-12-315,533,527USD
At 2024-06-3094,925USD
At 2023-12-3138,982USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-06-30380,310USD
At 2024-12-31521,010USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-06-30751,963USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-4,536,622USD91
2025-01-01 to 2025-06-30-8,413,481USD181
2024-04-01 to 2024-06-30-1,557,480USD91
2024-01-01 to 2024-06-30-3,047,722USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-302,339,230USD91
2025-01-01 to 2025-06-306,029,561USD181
2024-04-01 to 2024-06-30383,233USD91
2024-01-01 to 2024-06-30651,656USD182

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2024-04-01 to 2024-06-30777,681USD91
2024-01-01 to 2024-06-301,606,441USD182

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-04-01 to 2025-06-30302,106USD91
2025-01-01 to 2025-06-301,424,733USD181
2024-04-01 to 2024-06-30-777,680USD91
2024-01-01 to 2024-06-30-1,606,440USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-06-301,040,656USD181
2024-01-01 to 2024-06-30-45,905USD182

Inspect the source

Entity
OS THERAPIES INCORPORATED / CIK 0001795091
Captured
2026-09-21T17:27:44.173Z
SEC response SHA-256
669bcadf50e4b68c7e4f2d8dd624a583f81eb742fe94fe68568915c3f814e025

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001795091.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))